Source: Annals of Oncology, doi:10.1093/annonc/mdp541
Author: R. Rauck et al.

Background:
Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer. The objective of this study was to evaluate the efficacy of FBSF at doses of 200–1200 µg in the management of breakthrough pain in patients with cancer receiving ongoing opioid therapy.

Patients and methods:
This was a multicenter, randomized, double-blind, placebo-controlled, multiple-crossover study that included opioid-tolerant adult patients with chronic cancer pain who experienced one to four daily episodes of breakthrough pain. The primary efficacy assessment was the sum of pain intensity differences at 30 min (SPID30) postdose.

Results:
The intent-to-treat population consisted of 80 patients with 1 post-baseline efficacy assessment. The least-squares mean (LSM ± SEM) of the SPID30 was significantly greater for FBSF-treated episodes of breakthrough pain than for placebo-treated episodes (47.9 ± 3.9 versus 38.1 ± 4.3; P = 0.004). There was statistical separation from placebo starting at 15 min up through 60 min (last time point assessed). There were no unexpected adverse events (AEs) or clinically significant safety findings.

Conclusions:
FBSF is an effective option for control of breakthrough pain in patients receiving ongoing opioid therapy. In this study, FBSF was well tolerated in the oral cavity, with no reports of treatment-related oral AEs.

Authors:
R. Rauck1, J. North1, L. N. Gever2, I. Tagarro3 and A. L. Finn4

Authors’ affiliations:
1 Carolinas Pain Institute, Winston-Salem, NC
2 Meda Pharmaceuticals, Inc., Somerset, NJ, USA
3 Meda Pharmaceuticals, Madrid, Spain
4 BioDelivery Sciences International, Inc., Raleigh, NC, USA

Note:
Full text article is available here.